The global pharmaceutical CXO industry is no longer driven only by large drug companies. Behind many blockbuster medicines, vaccines, biologics, and biosimilars, there is a rapidly growing network of CROs, CDMOs, and CRDMOs helping pharmaceutical firms develop, test, manufacture, and commercialize drugs faster than ever before.
Companies like Samsung Biologics and IQVIA are now playing a central role in the pharmaceutical pipeline ecosystem.
IQVIA: Turning Healthcare Data Into a Multi-Billion Dollar Drug Development Machine
Few companies show the scale of pharmaceutical outsourcing better than IQVIA. In 2025, the company generated more than $16.3 billion in revenue, while its R&D Solutions business alone contributed nearly $8.9 billion. Even more impressive is its contracted backlog of $32.7 billion, showing how strongly pharmaceutical companies continue to outsource clinical trials and research operations.
But IQVIA’s real strength lies in data.
The company processes more than 4 billion prescription claims every year and manages over 1.2 billion patient records globally. Operating across more than 100 countries, IQVIA has quietly become one of the world’s largest healthcare intelligence platforms.
As pharmaceutical companies race to develop cancer drugs, obesity treatments, and personalized medicines, they increasingly rely on IQVIA’s analytics, trial management, and real-world evidence systems to reduce risk and speed up approvals.
This shift is changing the economics of the pharmaceutical industry. Instead of building massive internal trial operations, many pharma firms now outsource large portions of development to specialized partners.
Pharmaceutical CXO Companies Statistics
| Company | Revenue / Contracts | Key Data |
|---|---|---|
| IQVIA | $16.3B revenue | $32.7B backlog, 1.2B patient records |
| Samsung Biologics | ₩5.24T contracts | 784,000L manufacturing capacity |
| Lonza | CHF3.6B sales | 86% revenue from CDMO business |
| Thermo Fisher Scientific | $43B+ revenue | 100+ pharma manufacturing sites |
| WuXi Biologics | Multi-billion revenue | 580,000L+ biologics capacity |
| ICON plc | $8B+ revenue | 20,000+ clinical projects yearly |
| Catalent | $4B+ revenue | 50+ global facilities |
| Medpace | $2B+ revenue | Oncology-focused trials |
Samsung Biologics: Building One of the World’s Largest Drug Manufacturing Networks
While IQVIA dominates data and clinical outsourcing, Samsung Biologics is becoming one of the biggest forces in biologics manufacturing.
The South Korean company now operates a massive 784,000-liter biologics production capacity, making it one of the largest biologics CDMOs in the world. Its newest Plant 5 alone adds 180,000 liters of capacity.
In 2025, Samsung Biologics secured cumulative contracts worth more than ₩5.24 trillion, including a single U.S. pharmaceutical manufacturing deal valued at approximately $1.29 billion.
These numbers reflect a major global trend: pharmaceutical companies increasingly prefer outsourcing expensive biologics production rather than building their own facilities.
Manufacturing modern biologic drugs requires highly specialized infrastructure, strict regulatory compliance, and billions of dollars in investment. By partnering with companies like Samsung Biologics, drug developers can scale production faster while reducing capital costs.
The company is also expanding aggressively into the United States through acquisitions and new investments, showing how strategically important biologics manufacturing has become.
Lonza, WuXi Biologics, and Thermo Fisher Are Expanding the Global Pipeline Ecosystem
The pharmaceutical CXO industry is no longer dominated by a few Western companies.
Swiss giant Lonza reported CHF3.6 billion in first-half 2025 sales, with its CDMO business contributing nearly 86% of total revenue. Meanwhile, WuXi Biologics continues expanding global manufacturing capacity beyond 580,000 liters.
At the same time, Thermo Fisher Scientific has transformed its Patheon division into one of the world’s largest pharmaceutical services platforms, operating more than 100 global sites.
Together, these companies are creating a new pharmaceutical infrastructure layer that supports everything from early drug discovery to commercial manufacturing.
Why Investors Are Watching Pharmaceutical CXO Companies Closely
Investors are increasingly attracted to pharmaceutical outsourcing firms because of their long-term contracts, recurring revenue, and strong visibility into future demand.
Unlike traditional pharmaceutical companies that depend heavily on individual drug approvals, CROs and CDMOs often generate stable revenue from hundreds of clients simultaneously.
Backlog size, manufacturing utilization, and clinical pipeline exposure have become critical financial indicators across the industry.
As biologics, cell therapies, biosimilars, and AI-driven drug development continue expanding, the pharmaceutical CXO industry is evolving from a support service into one of the most important growth engines in global healthcare.
Pharmaceutical CXO Industry & Government Statistics
| Area | Real Statistics | Impact |
|---|---|---|
| FDA Drug Approvals | 50+ novel drugs approved yearly | Higher CRO/CDMO demand |
| U.S. Healthcare Spending | $4.5T+ annually | Expands drug commercialization |
| NIH Research Budget | $47B+ yearly | Supports biotech pipelines |
| India Manufacturing | 600+ US FDA-approved plants | Major global CDMO hub |
| IQVIA Data Scale | 4B prescription claims yearly | Large healthcare analytics ecosystem |
| Samsung Biologics | 784,000L capacity | One of largest biologics CDMOs |
| WuXi Biologics | 580,000L+ capacity | Expanding biologics outsourcing |
| Thermo Fisher | 100+ pharma service sites | Global drug manufacturing support |
Our experts have built a platform where all your Pharmaceutical Market insights, statistical data, country trends, and competitor strategies come together in one easy-to-use space. No more jumping between reports; everything you need is at your fingertips. Visit and access the dashboard to explore the market like never before.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is sister firm of Towards Healthcare Research and Consulting, provides strategic intelligence and research expertise across the pharmaceutical market, including branded drugs, generic medicines, biologics, biosimilars, specialty pharmaceuticals, OTC products, and drug delivery systems. We support pharmaceutical companies with market analysis, pipeline assessment, and competitive insights to help drive innovation, strengthen commercialization strategies, and capture emerging growth opportunities in the evolving healthcare landscape.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium